References
- Wesson D , LingW . The clinical opiate withdrawal scale (COWS) . J. Psychoactive Drugs35 , 253 – 259 ( 2003 ).
- Williams J , ChristieM , ManzoniO . Cellular and synaptic adaptations mediating opioid dependence . Physiol. Rev.81 , 299 – 343 ( 2001 ).
- Dahlstroem A , FuxeK . Evidence for the existence of monoamine-containing neurons in the central nervous system . Acta Physiol. Scand.232 , 1 – 55 ( 1964 ).
- Moore R , BloomF . Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems . Annu. Rev. Neurosci.2 , 113 – 168 ( 1979 ).
- Foote S , BloomF , Aston-JonesG . Nucleus locus ceruleus: new evidence of anatomical and physiological specificity . Physiol. Rev.63 , 844 – 914 ( 1983 ).
- Ouyang H , LiuS , ZengW , LevittR , CandiottiK , HaoS . An emerging new paradigm opioid withdrawal: a critical role for glia-neuron signaling in the periaqueductal gray . Sci. World J.2012 , 1 – 9 ( 2012 ).
- Kreek M , KoobG . Drug dependence: stress and dysregulation of brain reward pathways . Drug Alcohol Depend.51 ( 1-2 ), 23 – 47 ( 1998 ).
- Krantz M , MehlerP . Treating opioid dependence growing implications for primary care . Arch. Intern. Med.164 , 277 – 288 ( 2004 ).
- Gowing L , AliR , WhiteJM , MbeweD . Buprenorphine for managing opioid withdrawal . Cochrane Database Syst. Rev. (Online)2 , Cd002025 ( 2017 ).
- US FDA . FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults ( 2018 ). https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm .
- Greenwald MK , ComerSD , FiellinDA . Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy . Drug Alcohol Depend.144 , 1 – 11 ( 2014 ).
- Su MK , LopezJH , CrossaA , HoffmanRS . Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome . Am. J. Emerg. Med.36 ( 11 ), 1951 – 1956 ( 2018 ).
- Rehni AK , JaggiAS , SinghN . Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets . CNS Neurol. Disord. Drug Targets12 ( 1 ), 112 – 125 ( 2013 ).
- Stowe G , SchlosburgJ , VendruscoloLet al. Developing a vaccine against multiple psychoactive targets: a case study of heroin . CNS Neurol. Disord. Drug Targets10 ( 8 ), 865 – 875 ( 2011 ).